The aim of the studies described in this thesis was to investigate the potential of (pre)targeted radioimmunoimaging and radioimmunotherapy of prostate cancer with a humanized anti-TROP-2 monoclonal antibody (hRS7) and an anti-TROP-2 x anti-HSG bispecific monoclonal antibody (TF12).